PMHNP Scope of Practice for Depression in Florida

If you’re a psychiatrist or PMHNP treating depression via telehealth, you’ve probably asked yourself: Can I prescribe stimulants for a patient with treatment-resistant depression who also has ADHD — without ever meeting them in person? What if they’re in Florida? Texas? Do I need a collaborating physician if I’m an NP in California versus Pennsylvania?

The regulatory landscape for telehealth prescribing has been shifting rapidly since COVID, and 2025–2026 brings both clarity and new questions. Let’s cut through the confusion and talk about what actually matters for your practice.

The Big Picture: Federal DEA Rules Through 2026

Here’s the headline: you can still prescribe controlled substances via telehealth without an initial in-person visit through December 31, 2026 — thanks to the fourth extension of COVID-era flexibilities announced by DEA and HHS in January 2026.

What This Means for Depression Treatment

Most antidepressants (SSRIs, SNRIs, bupropion, mirtazapine) aren’t controlled substances, so federal DEA rules don’t restrict them at all. You’ve always been able to prescribe these via telehealth if your state allows it and standard of care is met.

But depression treatment often involves controlled substances:

• Benzodiazepines (Schedule IV) for comorbid anxiety or insomnia
• Stimulants (Schedule II) for treatment-resistant depression or comorbid ADHD
• Esketamine (Schedule III) administered in clinical settings for severe cases

Under normal circumstances, the Ryan Haight Act requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. During COVID, that requirement was suspended. The good news: it’s still suspended through the end of 2026.

This means:

• A psychiatrist in New York can start a patient on Adderall via video for depression with ADHD
• A PMHNP in California can prescribe Ativan for a patient with severe anxiety complicating their depression
• A telepsychiatry provider in Illinois can manage a full medication regimen including controlled substances

All via telehealth. No in-person visit required by federal law.

The catch: This is temporary. DEA is working on permanent rules.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: DEA’s Proposed Permanent Telehealth Rules

In January 2025, DEA announced three proposed rules to replace the temporary extensions:

1. Special Registration for Telemedicine (Schedule III–V)

Any provider prescribing Schedule III–V controlled substances (like ketamine, testosterone, benzodiazepines) via telehealth would need to apply for a special DEA telemedicine registration. This is administrative — you’d register, pay a fee, meet certain standards (likely around record-keeping and PDMP checks), and you’re set.

2. Advanced Telemedicine Prescribing for Schedule II (Psychiatrists Only)

Here’s where it gets interesting for depression providers: DEA proposes an ‘Advanced Telemedicine Prescribing’ registration specifically for Schedule II substances (Adderall, Ritalin, Vyvanse). This would be available only to board-certified psychiatrists, hospice/palliative care physicians, nursing home physicians, and certain pediatric specialists.

Translation: Psychiatrists would retain the ability to prescribe stimulants via telehealth without an in-person visit — but they’d need this special registration. PMHNPs? The proposed rule doesn’t explicitly include them for Schedule II telehealth prescribing, which could create a practice limitation if finalized as written.

DEA is seeking public comment on whether to expand this to other specialties and what safeguards to include. If you’re a PMHNP who prescribes stimulants for depression or ADHD, submit a comment — professional organizations are lobbying for NP inclusion.

3. Platform Registration & National PDMP

DEA also wants telehealth platforms themselves to register and comply with reporting standards — a response to ‘pill mill’ telehealth companies during the pandemic. For individual providers, this mostly means if you work through a company like Klarity, the platform will handle compliance.

There’s also talk of a national Prescription Drug Monitoring Program to unify state-by-state tracking. This would actually simplify things for multi-state prescribers.

Bottom line: The regulatory environment is becoming more structured, not more restrictive. Telehealth prescribing for psychiatric care is here to stay — but expect some administrative hoops starting in 2027.

State-by-State Reality Check: Where You Can Practice Independently

Federal rules set the floor. States set the ceiling — and that ceiling varies wildly depending on whether you’re a psychiatrist or a PMHNP.

For Psychiatrists: Mostly Smooth Sailing

Psychiatrists have full prescriptive authority in every state. The only real barriers are:

• Licensure (you must be licensed in the state where the patient is located)
• State-specific telehealth rules (usually minimal)
• Controlled substance prescribing laws (a few states have quirks)

For PMHNPs: It Depends Where You Practice

Your scope of practice varies dramatically by state. Let’s break down the priority markets:

What this means practically:

If you’re a PMHNP in California or New York with the required experience, you can join a platform like Klarity and start seeing patients independently. In Texas or Florida, you’ll need a collaborating psychiatrist — either your own or one provided by the platform.

For psychiatrists: you’re good to go anywhere, provided you have the state license.

State-Specific Telehealth Prescribing Rules That Actually Matter

Most states allow telehealth prescribing if it meets the standard of care. But a few have rules worth knowing:

Texas: The Chronic Pain Exception

Texas law prohibits treating chronic pain with controlled substances via telemedicine unless stringent conditions are met (like recent in-person visits within 90 days). This is aimed at opioid prescribing.

For depression treatment: This doesn’t typically affect you. Prescribing a benzodiazepine for anxiety or a stimulant for ADHD isn’t ‘chronic pain management.’ But if you have a patient whose depression overlaps with chronic pain requiring long-term opioids or benzodiazepines, you’d need to be cautious and potentially arrange an in-person eval.

Texas also requires audio-visual encounters for new patients — phone-only won’t cut it for establishing the relationship.

Florida: The Psychiatric Exception for Schedule II

Florida law says you cannot prescribe Schedule II controlled substances via telehealth — except for psychiatric disorders, inpatient care, hospice, or nursing home residents.

Translation: You can absolutely prescribe Adderall, Ritalin, or Vyvanse via telehealth for depression or ADHD in Florida, as long as it’s part of a documented psychiatric treatment plan. Florida carved out this exception specifically to preserve access to mental health care.

For Schedule III–V (like benzos or Ambien), there’s no restriction.

Florida also allows out-of-state physicians to register for telehealth practice without a full Florida license — a huge opportunity if you’re licensed elsewhere. PMHNPs can do this too, but you’ll still need a Florida supervising psychiatrist.

California: Audio-Visual Standard of Care

California doesn’t have specific telehealth prescribing restrictions beyond standard of care. During COVID, they allowed audio-only mental health visits — and many of those flexibilities remain for Medicaid patients.

Key point: California is not in the Interstate Medical Licensure Compact. If you want to treat California patients, you need a full California license (physicians) or California APRN license (NPs). No shortcuts.

Pennsylvania: No Formal Telehealth Law (Yet)

Pennsylvania has tried multiple times to pass comprehensive telehealth legislation — it’s stalled each time. The result: you practice under general standard of care guidance from the Department of State.

Pennsylvania allows telehealth prescribing if appropriate. The main requirements:

• Proper licensure
• Informed consent for telehealth
• Documentation equivalent to in-person
• For NPs: a collaborative agreement on file

Pennsylvania does mandate e-prescribing for controlled substances and PDMP checks. Aside from that, it’s straightforward — just document well.

The Economics: Why Telehealth Beats DIY Marketing

Let’s talk about the business reality most providers face: patient acquisition.

If you go solo, acquiring psychiatric patients through DIY marketing is expensive and uncertain:

The Real Cost of DIY Marketing

• SEO: Takes 6–12 months of consistent investment (content, site optimization, local listings) before you see meaningful patient flow. Budget $2,000–$5,000/month if you’re hiring an agency.
• Google Ads: Mental health keywords cost $15–$40+ per click. Most clicks don’t convert. A realistic cost per booked patient through PPC is $200–$400+ when you factor in testing, optimization, and no-shows.
• Directory Listings: Psychology Today, Zocdoc, and others charge monthly fees ($30–$100+) and you compete with hundreds of providers. Zocdoc also charges per booking ($35–$100+). Total monthly cost adds up fast.
• Staff Time: Handling leads, qualifying patients, managing no-shows from cold traffic — this is real overhead.

Bottom line: Acquiring a qualified psychiatric patient through DIY channels realistically costs $200–$500+ when you account for all expenses, failed campaigns, and opportunity cost. And that’s if you have the expertise and patience to stick with it.

The Klarity Health Model: Pay Only for Qualified Patients

Klarity uses a pay-per-appointment model similar to Zocdoc’s booking fees, but with key differences:

What you get:

• Pre-qualified patients already matched to your specialty, availability, and insurance panels
• No upfront marketing spend or monthly subscription fees
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs or tech headaches)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The economic case: Instead of gambling $3,000–$5,000/month on marketing channels with uncertain ROI, you pay a standard listing fee per new patient lead that books with you. That’s guaranteed ROI vs. rolling the dice on SEO or PPC.

For new providers or those scaling up: Platforms that handle patient acquisition remove the risk entirely. You get patient flow from day one without the months-long ramp of DIY marketing or the expertise required to run effective campaigns.

DIY marketing can eventually be cost-effective if you have the budget, expertise, and patience — but for most providers, especially those starting out or wanting to scale without operational complexity, paying per qualified patient is the smart economic choice.

FAQ: Questions Providers Actually Ask

Q: Can I prescribe antidepressants via telehealth to a new patient I’ve never met in person?

A: Yes, absolutely. Non-controlled antidepressants (SSRIs, SNRIs, bupropion, etc.) are not subject to DEA telehealth restrictions. As long as you meet your state’s standard of care (proper evaluation, informed consent, documentation), you’re fine.

Q: Can I prescribe Adderall or benzodiazepines via telehealth right now?

A: Yes, through December 31, 2026. The DEA’s temporary extension allows prescribing Schedule II–V controlled substances via telehealth without an initial in-person visit. After 2026, you may need to apply for a special telemedicine registration.

Q: What happens in 2027 when the DEA extension expires?

A: DEA is expected to finalize permanent rules before then. The proposed rules would allow psychiatrists to continue prescribing Schedule II substances via telehealth (with a special registration). PMHNPs should monitor whether the final rule includes NPs for Schedule II prescribing.

If rules aren’t finalized, DEA could extend the flexibilities again or require in-person exams — but the trend is toward permanent telehealth accommodations for psychiatric care, not restrictions.

Q: I’m a PMHNP in Texas. Can I practice via telehealth independently?

A: No. Texas requires all APRNs to have a Prescriptive Authority Agreement with a physician. You’ll need a collaborating psychiatrist (either one you arrange yourself or through a platform). The physician doesn’t need to be present on your video calls, but they must be available for consultation and you must meet regularly for case discussions.

Q: Can an out-of-state psychiatrist treat patients in multiple states via telehealth?

A: Only if you’re licensed in each state where your patients are located. Some states participate in the Interstate Medical Licensure Compact (IMLC), which streamlines getting licenses in multiple states (Texas, Illinois, Pennsylvania, Florida are members). California and New York are not.

Florida has a unique out-of-state telehealth registration that’s cheaper and faster than full licensure — but you can only practice via telehealth (no in-person visits) and must follow Florida’s rules.

Q: Do I need to check the state prescription monitoring program (PDMP) for every controlled substance prescription?

A: Yes, in most states. States like California (CURES), Florida (E-FORCSE), Pennsylvania, Illinois, and Texas all require PDMP checks before prescribing controlled substances. Some states require it for every prescription; others only for new patients or certain schedules. Check your state’s specific law — but integrating PDMP checks into your workflow is standard practice now.

Q: Can I use phone-only (audio-only) for telehealth psychiatric visits?

A: It depends on the state and clinical situation. During COVID, many states allowed audio-only for mental health. Some (like New York and California for Medicaid) have extended those flexibilities.

Texas specifically requires audio-visual for new patients to establish a relationship. Other states allow audio-only if it meets standard of care.

Best practice: Use video when possible. Audio-only is acceptable for follow-ups with established patients or when video isn’t feasible (patient in rural area with poor internet, etc.), but document why.

Q: What’s the difference between treating depression as a psychiatrist vs. PMHNP in terms of scope?

A: Clinically, both can diagnose and treat depression, prescribe medications, and provide therapy. The differences are regulatory:

• Psychiatrists have full independent practice authority in all states. No supervision required. Can prescribe all medications without restrictions (beyond DEA/state law).
• PMHNPs have independent authority in some states (CA, NY, IL with FPA), but require physician collaboration in others (TX, FL, PA). In states with collaboration requirements, the physician must be available for consultation and may need to co-sign certain prescriptions or review charts.

Under the proposed DEA rules, only psychiatrists (not PMHNPs) would be explicitly allowed to prescribe Schedule II substances via telehealth under the Advanced Telemedicine Prescribing registration. This is a potential future limitation for NPs unless the rule is modified.

Q: Does Klarity Health handle credentialing and licensing for me?

A: Klarity can assist with credentialing for insurance panels, but you are responsible for maintaining your own state licenses in every state where you treat patients. Klarity’s platform handles the patient-facing tech (scheduling, EHR, telehealth video, billing) — but licensure, DEA registration, and malpractice insurance are your responsibility as the provider.

Klarity’s support team can guide you through multi-state licensing if you want to expand your practice footprint.

What This Means for Your Practice in 2025–2026

If you’re a psychiatrist, the regulatory environment is favorable:

• You can prescribe any necessary medication for depression via telehealth (including controlled substances) through 2026 with minimal restrictions
• Expect to register with DEA for a special telemedicine credential starting in 2027
• Focus on getting licensed in high-demand states (California, Texas, Florida, New York if you want volume; use IMLC for efficiency)
• Platforms like Klarity remove patient acquisition risk — you see patients from day one without marketing overhead

If you’re a PMHNP, your strategy depends on location:

• In full-practice states (CA, NY, IL with FPA), you have the same autonomy as a psychiatrist for depression treatment — take advantage of it
• In collaborative-practice states (TX, FL, PA), partner with a collaborating psychiatrist or join a platform that provides one
• Monitor the DEA’s final rules on Schedule II prescribing — if PMHNPs are excluded from the Advanced Telemedicine Prescribing registration, that could limit your ability to independently prescribe stimulants via telehealth after 2026
• Consider getting your full practice authority if you’re in a state that offers it (IL requires 4,000 hours + training, for example)

For both: The trend is toward expanded telehealth access for mental health care, not restrictions. The key is staying compliant with licensing, documentation, and evolving federal rules.

Ready to Build a Telehealth-First Depression Practice?

The regulatory landscape has never been more favorable for telepsychiatry — and the demand has never been higher. Depression is the most common psychiatric condition, medication management is a core competency for psychiatrists and PMHNPs, and telehealth removes geographic barriers that limit access.

Whether you’re looking to start a telepsychiatry practice, expand into new states, or scale beyond the patient volume DIY marketing can deliver, Klarity Health offers a smarter path: pre-qualified patients, built-in infrastructure, and pay-per-appointment economics that eliminate upfront risk.

Join Klarity’s provider network and start seeing depression patients via telehealth — without the marketing overhead, tech headaches, or months-long ramp time of solo practice.

👉 Explore Klarity’s Provider Platform and see how we handle patient acquisition, credentialing, and telehealth infrastructure so you can focus on clinical care.

Citations & Sources

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026). U.S. Department of Health & Human Services. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access’ (January 16, 2025). U.S. Drug Enforcement Administration. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Statutes §456.47 – ‘Use of Telehealth to Provide Services.’ Florida Legislature Online Sunshine (2019, updated through 2025). https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Texas Administrative Code Title 22 §174.5 – ‘Telemedicine Medical Service, Telemedicine Health Service, and Telehealth Service.’ Texas Medical Board (last updated January 15, 2025). https://txrules.elaws.us/rule/title22chapter174sec.174.5

5. California AB 890 Implementation – Board of Registered Nursing, ‘Nurse Practitioner Practice Under AB 890’ (regulations effective 2023–2024). California Board of Registered Nursing. https://www.rn.ca.gov/practice/ab890.shtml

Note: All regulatory information in this article is current as of February 2026 and is based on official government sources, state statutes, and federal agency announcements. Regulations may change — providers should verify current requirements with their state licensing boards and the DEA before making practice decisions.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=These%20rules%20are%20a%20result,temporary%20rule%20until%20December%202025
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=is%20accessible%20for%20medical%20care,is%20being%20prescribed%20controlled%20medication
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%20law%20previously%20allowed,based%20on%20only
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,person%20setting
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,be
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://txrules.elaws.us/rule/title22chapter174sec.174.5#:~:text=,through%20a%20telemedicine%20medical%20service